## SOLV: Solventum Corporation - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.47 indicates fundamental undervaluation. Quality metrics strong (ROE 37%). Consistent execution (4/4 quarters beat estimates). Caution: momentum weakening (-5.3% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($78.81)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 8
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Solventum (SOLV): Reassessing Valuation After a Strong Year-to-Date Rally and Recent Pullback**
- Source: Yahoo Finance | 20251210T051100 | Somewhat-Bullish | Relevance: 99%
-  Solventum (SOLV) has seen a significant 22% year-to-date rally, despite a recent pullback, outperforming the broader market. The article questions whether the stock, currently trading near analyst targets with modest earnings growth, still offers an attractive discount or if its future growth is already priced in. Simply Wall St's narrative suggests Solventum is 3.2% undervalued, with a fair value of $82.80, attributing potential upside to strategic optimization, a strong balance sheet for M&A, and improving margins.

**2. Solventum Corp. stock falls Tuesday, underperforms market**
- Source: MarketWatch | 20251209T210835 | Neutral | Relevance: 99%
-  Solventum Corp. (SOLV) saw its stock fall by 3.01% on Tuesday, closing at $80.11. This decline occurred during a generally negative trading session where the S&P 500 Index dropped 0.09% and the Dow Jones Industrial Average fell 0.38%. This marks the second consecutive day of losses for Solventum Corp.

**3. Solventum Corporation (SOLV): A Bull Case Theory**
- Source: Finviz | 20251209T200815 | Bullish | Relevance: 99%
- This article summarizes a bull thesis on Solventum Corporation (SOLV), a healthcare company recently spun off from 3M. Despite initial high debt, the company has deleveraged significantly through asset sales and is now positioned for a turnaround under strong leadership. The thesis highlights attractive valuation, clear growth targets, and a favorable risk-reward profile for patient investors, while acknowledging risks like potential PFAS litigation.

**4. Solventum Corp. stock falls Tuesday, underperforms market**
- Source: MarketWatch | 20251209T210835 | Neutral | Relevance: 98%
- Solventum Corp. (SOLV) saw its stock price drop by 3.01% to $80.11 on Tuesday, underperforming the broader market. The S&P 500 Index and Dow Jones Industrial Average also experienced declines, making it the second consecutive day of losses for Solventum Corp.

**5. Solventum Corp. stock falls Tuesday, underperforms market**
- Source: MSN | 20251209T215115 | Neutral | Relevance: 98%
- This article reports that Solventum Corp. (SOLV) stock experienced a decline on Tuesday, underperforming the broader market. The stock fell by 1.94%, closing at $62.62, while the S&P 500 saw a gain. This performance comes as the stock had previously achieved a 52-week high, with the recent decline placing it below its 50-day moving average.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | BTIG | $100 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | BTIG | up | Buy |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.6% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 0 |

**Top Holders:**
- Vanguard Group Inc: 9.9% (+5.3%)
- Independent Franchis: 7.4% (+27.2%)
- Blackrock Inc.: 5.9% (+6.1%)
- Trian Fund Managemen: 4.9% (0.0%)
- State Street Corpora: 3.6% (+1.8%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-5.3% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.47 suggests fair value with growth premium. Forward P/E 13.0x stretched relative to 5% growth. Quality metrics strong (ROE 37%, margin 18%). Institutional flow bullish (8 buying vs 0 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $14.4B |
| Beta | 1.00 |
| 52W Range | $60.70 - $88.20 |
| Short Interest | 2.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.47 |
| Forward P/E | 13.0 |
| Current P/E | 13.7 |
| YoY Growth | 5.4% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 4.3% to -1.0% (-5.3% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 5.0pp (needs >4.0% for momentum thesis). MRS_5 turning positive (0.2%) - potential reversal signal. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-0.53), momentum weakening. RSI neutral at 60.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -1.03% (CS: 38) | Neutral |
| RSI_14 | 59.6 | Neutral |
| MACD Histogram | -0.53 | Bearish |
| vs SMA20 | 1.011x | Above |
| vs SMA50 | 1.095x | Above |
| vs SMA200 | 1.127x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $82.79
- **Stop Loss:** $78.81 (4.8% risk)
- **Target:** $90.75 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 346
- **Position Value:** $28,645.34
- **Portfolio %:** 28.65%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | IGNITION (Zone D) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-02-26 (Est: $1.49)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.43 | $1.50 | +4.7% |
| 2025Q2 | $1.45 | $1.69 | +16.2% |
| 2025Q1 | $1.22 | $1.34 | +9.7% |
| 2024Q4 | $1.31 | $1.41 | +7.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*